Genticel develops gentle therapeutic vaccines to treat early-stage human papilloma virus infections. The lead vaccine, GTL001, targets high-risk HPV 16 and 18 infections causing c 75% of cervical cancers in North America and the EU. There is no therapeutic vaccine to treat up to 12m women (in these markets). Phase II data, due in H116, could enable a major partnering deal to fund Phase III. A second product, GTL002, based on an improved proprietary platform (Vaxiclase), could enter trials in
01 Sep 2015
Gentle therapy; dangerous infections
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Gentle therapy; dangerous infections
Genticel develops gentle therapeutic vaccines to treat early-stage human papilloma virus infections. The lead vaccine, GTL001, targets high-risk HPV 16 and 18 infections causing c 75% of cervical cancers in North America and the EU. There is no therapeutic vaccine to treat up to 12m women (in these markets). Phase II data, due in H116, could enable a major partnering deal to fund Phase III. A second product, GTL002, based on an improved proprietary platform (Vaxiclase), could enter trials in